Top Markets
#1 Pleasing Gold Pleasing Gold +1,543.14%
#2 PulseChain PulseChain +57.40%
#3 Ontology Gas Ontology Gas +36.19%
#4 Merlin's Seal BTC Merlin's Seal BTC +31.77%
#5 BOOK OF MEME BOOK OF MEME +30.30%
#6 Collect on Fanable Collect on Fanable +24.02%
#7 Neiro Neiro +20.79%
#8 Unit Pump Unit Pump +20.03%
#9 Pump.fun Pump.fun +20.03%
#10 Nockchain Nockchain +19.80%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

NLTX
Rank in Stocks #26679
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused... Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Share Price
$3.49
Last synced: 2023-12-19
Market Cap
$38.68M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Neoleukin Therapeutics, Inc. (NLTX)

Category

Healthcare
Revenue for Neoleukin Therapeutics, Inc. (NLTX)
Revenue in Aug 2026 TTM: 0
According to Neoleukin Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Neoleukin Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN